Valuation of target companies in mergers and acquisitions: the case of Aspen Pharmacare and Adcock Ingram

Simple item page
dc.contributor.authorMadisa, Nompumelelo
dc.date.accessioned2016-08-25T13:09:52Z
dc.date.available2016-08-25T13:09:52Z
dc.date.issued2016-08-25
dc.descriptionMASTER OF MANAGEMENT IN FINANCE & INVESTMENT (MMFI) 2015 RESEARCH REPORTen_ZA
dc.description.abstractThis paper assesses shareholder wealth creation in target and acquiring companies as a result of an acquisition, in particular, a hostile takeover. The paper reviews existing mergers and acquisitions literature and also considers a case study in order to review some practical results. The case study of the Bidvest Group hostile takeover of Adcock Ingram Pharmaceuticals that took place in January 2014 in South Africa is reviewed. A detailed qualitative and quantitative analysis is conducted to ascertain and quantify shareholder wealth creation after the takeover. The analysis conducted included a financial assessment using relevant financial indicators, an analysis of existing literature and interviews with key board directors of Adcock Ingram Pharmaceuticals. To ascertain whether the results of the target company, Adcock Ingram Pharmaceuticals, are either in line, below or above industry performance after the takeover, Adcock Ingram Pharmaceuticals’ results are benchmarked against Aspen Pharmacare Holding’s results. Majority of the findings literature reviewed are that target company shareholder gains exceed acquiring company shareholder gains post an acquisition. The findings of this research are that target company (Adcock Ingram Pharmaceuticals) shareholders are worse off whilst acquiring company (Bidvest Group) shareholders continue to increase their wealth after the takeover. Possible reasons for these results, which contradict majority of the existing literature on wealth gains post a merger or acquisition, are given.en_ZA
dc.identifier.urihttp://hdl.handle.net/10539/20933
dc.language.isoenen_ZA
dc.subject.lcshConsolidation and merger of corporations--South Africa
dc.subject.lcshStockholders--South Africa
dc.subject.lcshCorporations--Valuation
dc.titleValuation of target companies in mergers and acquisitions: the case of Aspen Pharmacare and Adcock Ingramen_ZA
dc.typeThesisen_ZA
Files
Original bundle
Now showing 1 - 2 of 2
No Thumbnail Available
Name:
ABSTRACT 4 August 2015 Final.pdf
Size:
189.04 KB
Format:
Adobe Portable Document Format
Description:
Download
No Thumbnail Available
Name:
Valuation of target companies in mergers and acquisitions 9809965D.pdf
Size:
682.73 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
ETD Collection